PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced it will release its fourth quarter and full year 2021 financial results on February 9, 2022, before the U.S. market opens. The company will hold a conference call at 8:30 AM ET to discuss these results and provide operational updates. PolyPid specializes in developing targeted, long-lasting therapeutics through its proprietary PLEX technology, with its lead product candidate, D-PLEX100, currently undergoing Phase 3 trials aimed at preventing surgical site infections.

Positive

• PolyPid's lead product candidate, D-PLEX100, is in Phase 3 clinical trials, indicating progress in developing innovative therapeutics.
• Upcoming financial results and operational updates may provide insights into the company's performance and strategic direction.

Negative

• None.

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, February 9, 2022
Time:	8:30 AM Eastern Time
United States:	+1 877-870-9135
Israel:	+972 1809 213-985
International:	+44 (0) 2071 928338
Conference ID:	6092321
Webcast:	https://edge.media-server.com/mmc/p/fxz7727t

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).

For additional company information, please visit polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com

FAQ

When will PolyPid report its financial results for Q4 and full year 2021?

PolyPid will report its financial results on February 9, 2022, before the U.S. market opens.

What is PolyPid's lead product candidate?

PolyPid's lead product candidate is D-PLEX100, which is currently in Phase 3 clinical trials.

What technology does PolyPid utilize for its therapeutics?

PolyPid utilizes its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology for developing therapeutics.

At what time is PolyPid's conference call scheduled on February 9, 2022?

The conference call is scheduled for 8:30 AM Eastern Time on February 9, 2022.